Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

D. James, Nicholas; S. de Bono, Johann; Spears, Melissa; W. Clarke, Noel; D. Mason, Malcolm; P. Dearnaley, David; Ritchie, A.W.S.; Amos, Claire; Gilson, Clare; J. Jones, Robert; Matheson, David; Millman, Robin; Attard, Gerhardt; Chowdhury, Simon; Cross, William; Gillessen, Silke; Parker, Christopher; M. Russell, John; Berthold, Dominik; Brawley, Chris; Adab, F.; Aung, San; Birtle, Alison; Bowen, Jo; Brock, Susannah; Chakraborti, Prabir; Ferguson, Catherine; Gale, Joanna; Gray, Emma; Hingorani, Mohan; Hoskin, Peter; Lester, J.F.; Malik, Zafar; McKinna, Fiona; McPhail, Neil; Money‐Kyrle, Julian; M. O’Sullivan, Joe; Parikh, Omi; Protheroe, Andrew; Robinson, Angus; Srihari, Narayanan; Thomas, Carys; Wagstaff, John; Wylie, James; Zarkar, Anjali; Parmar, Mahesh; R. Sydes, Matthew

doi:10.1056/nejmoa1702900

Public

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

Published in New England Journal of Medicine • Jun 3, 2017

Authors:

Nicholas D. James

Johann S. de Bono

Melissa Spears

Abstract

BACKGROUND: Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial design. METHODS: We randomly assigned patients in a ...

Subject

Abiraterone acetate

Prostate cancer

Abiraterone

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!